Dr. Stavroula Otis

Hematology
1401 N Tustin Ave, Suite 220, 
Santa Ana, CA 
Offers Telehealth
1401 N Tustin Ave, Suite 220, 
Santa Ana, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stavroula Otis is a Hematologist in Santa Ana, California. Dr. Otis is rated as an Experienced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. Her top areas of expertise are Follicular Lymphoma, Myelodysplastic Syndrome (MDS), Agranulocytosis, and Anemia.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in CA
Hospital Affiliations
Providence St. Joseph Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

CENTER FOR CANCER AND BLOOD DISORDERS
1401 N Tustin Ave, Suite 220, Santa Ana, CA 92705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Unknown
Publish Date: October 15, 2021
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

1 Total Publications

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2013
Similar Doctors
Distinguished in Congenital Antithrombin 3 Deficiency
Dr. Minh D. Nguyen
Hematology Oncology | Oncology | Hematology
Distinguished in Congenital Antithrombin 3 Deficiency
Dr. Minh D. Nguyen
Hematology Oncology | Oncology | Hematology

USC Care Medical Group Inc

520 Superior Ave, Suite 300, 
Newport Beach, CA 
 (10.3 miles away)
949-474-5722
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Minh Nguyen is a Hematologist Oncology specialist and an Oncologist in Newport Beach, California. Dr. Nguyen is rated as a Distinguished provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Primary Lymphoma of the Brain.

Distinguished in Congenital Antithrombin 3 Deficiency
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology
Distinguished in Congenital Antithrombin 3 Deficiency
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (29.9 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Casey O'connell is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. O'connell is rated as an Elite provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. Her top areas of expertise are Polycythemia Vera, Myelofibrosis, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Splenectomy.

Advanced in Congenital Antithrombin 3 Deficiency
Dr. Wael A. Harb
Hematology Oncology | Oncology | Hematology
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Wael A. Harb
Hematology Oncology | Oncology | Hematology

Memorialcare Medical Foundation

1441 Avocado Ave, Suite 301, 
Newport Beach, CA 
 (10.1 miles away)
949-272-2095
Languages Spoken:
English
See accepted insurances

Wael Harb is a Hematologist Oncology specialist and an Oncologist in Newport Beach, California. Dr. Harb is rated as an Advanced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Lung Cancer, Breast Cancer, Protein C Deficiency, and Congenital Antithrombin 3 Deficiency.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Otis's expertise for a condition
ConditionClose
      View All 36 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile